ReviewWorld journal of gastroenterology2014
Chemotherapy for patients with gastric cancer after complete resection: a network meta-analysis.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- The order of surgery and chemotherapy matters: Multimodality therapy and stage-specific differences in survival in gastric cancer.Journal of surgical oncology · 2023Article
- Identification of a chemotherapy-associated gene signature for a risk model of prognosis in gastric adenocarcinoma through bioinformatics analysis.Journal of gastrointestinal oncology · 2022Article
- Effects ofFrontiers in pharmacology · 2022Article
- A systematic review and network meta-analysis protocol of adjuvant chemotherapy regimens for resected gastric cancer.Medicine · 2019Article
- Calponin 3 Regulates Cell Invasion and Doxorubicin Resistance in Gastric Cancer.Gastroenterology research and practice · 2019Article
- MicroRNA-613 induces the sensitivity of gastric cancer cells to cisplatin through targeting SOX9 expression.American journal of translational research · 2019Article
- A Novel Mechanism of Doxorubicin Resistance and Tumorigenesis Mediated by MicroRNA-501-5p-Suppressed BLID.Molecular therapy. Nucleic acids · 2018Article
- Transcription activated p73-modulated cyclin D1 expression leads to doxorubicin resistance in gastric cancer.Experimental and therapeutic medicine · 2018Article
- Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.Journal of experimental & clinical cancer research : CR · 2017Article
- Current adjuvant treatment modalities for gastric cancer: From history to the future.World journal of gastrointestinal oncology · 2016Review
- Multidrug Resistance-associated Protein-1 (MRP-1)-dependent Glutathione Disulfide (GSSG) Efflux as a Critical Survival Factor for Oxidant-enriched Tumorigenic Endothelial Cells.The Journal of biological chemistry · 2016Article
- A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.Drug design, development and therapy · 2016Article
- Multimodal treatment of gastric cancer in the west: Where are we going?World journal of gastroenterology · 2015Review
- Polyunsaturated fatty acids augment tumoricidal action of 5-fluorouracil on gastric cancer cells by their action on vascular endothelial growth factor, tumor necrosis factor-α and lipid metabolism related factors.Archives of medical science : AMS · 2015Article
- Submucosal injection solution for endoscopic resection in gastrointestinal tract: a traditional and network meta-analysis.Gastroenterology research and practice · 2015Review
- lncRNA ROR Promotes Gastric Cancer Drug Resistance.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo conduct a network meta-analysis to evaluate the effectiveness of different chemotherapy regimens for patients with gastric cancer.
methodsPubMed (1966-2011.12), the Cochrane Library (2011 Issue 2) and EMBASE (1974-2011.12) were searched with the terms "gastric cancer" and "chemotherapy", as well as the medical subject headings. References from relevant articles and conferences were also included. Patients who had previous gastric surgery, radiation before or after surgery or chemotherapy before surgery were excluded. In this study, only randomized controlled trials (RCTs) were considered, and the end-point was the overall mortality. Direct comparisons were performed using traditional meta-analysis whereas indirect comparisons were performed using network meta-analysis.
resultsIn total, 31 RCTs with 7120 patients were included. Five chemotherapy regimens, fluorouracil (FU) + BCNU, FU + methyl-CCNU (mCCNU), FU + cisplatin, FU + anthracyclines and FU + mitomycin c (MMC) + cytarabine (Ara-c), were found to be less beneficial in terms of overall mortality. In contrast, four chemotherapy regimens were effective for the patients after surgery, including FU + MMC + adriamycin (FMA), FU + MMC (FM), Tegafur and MMC, There was no significant difference in terms of overall mortality among these regimens. The evidence for the FM regimen and MMC regimen was poor. Additionally, the FMA regimen, which includes a variety of chemotherapy drugs and causes many side effects, was not better than the Tegafur regimen.
conclusionAlthough the four chemotherapy regimens were effective in patients with gastric cancer after surgery and the overall mortality revealed no significant difference among them in the network meta-analysis, thorough analysis of the results recommends Tegafur as the first-line adjuvant chemotherapy regimen for patients after complete resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.